We are excited to present our latest cell and gene therapy (CGT) white paper: Cold hard facts about cryogenic cell and gene therapy logistics.
In this publication, we present the findings of research we commissioned by Coleman Parkes Research. We surveyed decision-making executives and managers in supply chain operational roles in companies with CGTs in clinical trials or those with commercial products. The respondents answered various transportation and storage questions related to their companies' cell and gene therapies in development; these included:
How do they see the landscape for cryogenic transportation and storage services changing over the coming years? What is the expected rate of change?
- What are the key drivers of growth in cryogenic transportation for both clinical trials and commercialized products?
- Which critical challenges concerning cryogenic transportation and storage are they currently facing?
- What are the most critical factors they consider when selecting a cryogenic transportation and storage provider?
In this white paper, we not only present our survey results but also provide an overview of the current CGT logistics landscape; these therapies represent the leading edge of biomedical research. However, they pose challenges for companies seeking to transport their innovative treatments - whether for a clinical trial or for commercial distribution. From the requirement for delivery speed to cold-chain integrity, CGTs have particular logistical issues that we must all address, to build healthier futures for the lives of patients everywhere.
Download the white paper to access our survey results and learn more about how you can mitigate these risks and build robust logistics platforms that support the clinical development of these innovative therapies.